(Q37875055)

24 August 2017

1 reference

title

Recurrent Clostridium difficile infection: what are the treatment options? (English)

1 reference

24 August 2017

main subject

Clostridium difficile

0 references

2

Annelies Verbon

1 reference

24 August 2017

3

Ernst J Kuipers

1 reference

24 August 2017

author name string

Claire M F van Nispen tot Pannerden

series ordinal

1

1 reference

24 August 2017

publication date

1 May 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

71

1 reference

24 August 2017

issue

7

1 reference

24 August 2017

page(s)

853-868

1 reference

Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

Clinical manifestations, treatment and control of infections caused by Clostridium difficile.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

Clinical practice. Antibiotic-associated diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

Clostridium difficile-associated diarrhea: current strategies for diagnosis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

Nitazoxanide for the treatment of Clostridium difficile colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

The potential for airborne dispersal of Clostridium difficile from symptomatic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

Aerial dissemination of Clostridium difficile spores

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

The role of the intestinal tract as a reservoir and source for transmission of nosocomial pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

Nosocomial acquisition of Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

Fecal bacteriotherapy for recurrent Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

Clostridium difficile--associated disease in a setting of endemicity: identification of novel risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

Antimicrobial-associated risk factors for Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

Antibiotics and hospital-acquired Clostridium difficile-associated diarrhoea: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

Risk factors for Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

Risk Factors for Treatment Failure and Recurrence after Metronidazole Treatment for Clostridium difficile-associated Diarrhea.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

Clinical predictors and risk factors for relapsing Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

Meta-analysis to assess risk factors for recurrent Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

Recurrent Clostridium difficile infection: causality and therapeutic approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

How should we respond to the highly toxogenic NAP1/ribotype 027 strain of Clostridium difficile?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

Clostridium difficile: responding to a new threat from an old enemy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

Clostridium difficile and the disease it causes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis: case series and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

Metronidazole resistance in Clostridium difficile.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

In vitro activity of ramoplanin against Clostridium difficile, including strains with reduced susceptibility to vancomycin or with resistance to metronidazole

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

Emergence of reduced susceptibility to metronidazole in Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

Intravenous metronidazole for the treatment of Clostridium difficile colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

The case for vancomycin as the preferred drug for treatment of Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

Future novel therapeutic agents for Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

Rifaximin for the treatment of recurrent Clostridium difficile infection after liver transplantation: A case series

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

Rifaximin in treatment of recurrent Clostridium difficile-associated diarrhea: an uncontrolled pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

Rifaximin Redux: treatment of recurrent Clostridium difficile infections with rifaximin immediately post-vancomycin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

In vitro susceptibility of Clostridium difficile to rifaximin and rifampin in 359 consecutive isolates at a university hospital in Houston, Texas

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

Severe and refractory Clostridium difficile infection successfully treated with tigecycline and metronidazole

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

Nitazoxanide: a review of its use in the treatment of gastrointestinal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

A double-blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile-associated diarrhoea

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

In vitro activities of OPT-80 and comparator drugs against intestinal bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

Fidaxomicin (OPT-80) for the treatment of Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

Fidaxomicin versus vancomycin for Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

Toxin-binding treatment for Clostridium difficile: a review including reports of studies with tolevamer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

Bovine antibody-enriched whey to aid in the prevention of a relapse of Clostridium difficile-associated diarrhoea: preclinical and preliminary clinical data.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

Management of Clostridium difficile infection: thinking inside and outside the box.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

Clostridium difficile-associated diarrhoea: bovine anti-Clostridium difficile whey protein to help aid the prevention of relapses

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

A randomized, double-blind study comparing Clostridium difficile immune whey and metronidazole for recurrent Clostridium difficile-associated diarrhoea: efficacy and safety data of a prematurely interrupted trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

Treatment with monoclonal antibodies against Clostridium difficile toxins

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

The potential value of Clostridium difficile vaccine: an economic computer simulation model

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

The role of immunoglobulin for the treatment of Clostridium difficile infection: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridium difficile diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

The microecology of Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

Seven cases of fungemia with Saccharomyces boulardii in critically ill patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

Saccharomyces cerevisiae fungemia: an emerging infectious disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

Success of self-administered home fecal transplantation for chronic Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

Treatment of ulcerative colitis using fecal bacteriotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

Clostridium difficile infection in Europe: a hospital-based survey

21 January 2018

2 references

https://api.crossref.org/works/10.2165%2F11591230-000000000-00000

21 January 2018

12 December 2020

[Feces culture successful therapy in Clostridium difficile diarrhea]

1 reference

12 December 2020

Clostridium difficile toxin expression is inhibited by the novel regulator TcdC

1 reference

12 December 2020

Relapsing Clostridium difficile enterocolitis cured by rectal infusion of normal faeces

1 reference

12 December 2020

Treatment of Clostridium difficile-associated diarrhea and colitis

1 reference

12 December 2020

Antibiotic treatment for Clostridium difficile-associated diarrhea in adults

1 reference

12 December 2020

Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection

1 reference

12 December 2020

Failure of tigecycline to treat severe Clostridium difficile infection

1 reference

12 December 2020

Clostridium difficile-associated diarrhea treated with homologous feces

1 reference

12 December 2020

Changes in predominant bacterial populations in human faeces with age and with Clostridium difficile infection

1 reference

12 December 2020

Results of faecal donor instillation therapy for recurrent Clostridium difficile-associated diarrhoea

1 reference

12 December 2020

Clostridium difficile

1 reference

12 December 2020

Interruption of Recurrent Clostridium difficile-Associated Diarrhea Episodes by Serial Therapy with Vancomycin and Rifaximin

1 reference

12 December 2020

Clostridium difficile infection

1 reference

12 December 2020

Recurrent Clostridium difficile disease: epidemiology and clinical characteristics

1 reference

12 December 2020

Faecal pharmacokinetics of orally administered vancomycin in patients with suspected Clostridium difficile infection.

1 reference

12 December 2020

Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of Clostridium difficile-associated diarrhea

1 reference

12 December 2020

Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea

1 reference

12 December 2020

Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea

1 reference

12 December 2020

Treatment of recurrent Clostridium difficile-associated diarrhea by administration of donated stool directly through a colonoscope

1 reference

12 December 2020

Passive immunization of hamsters against disease caused by Clostridium difficile by use of bovine immunoglobulin G concentrate

1 reference

12 December 2020

Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea

1 reference

12 December 2020

Probiotics for recurrent Clostridium difficile disease

1 reference

12 December 2020

Oral bacitracin vs vancomycin therapy for Clostridium difficile-induced diarrhea. A randomized double-blind trial

1 reference

12 December 2020

Antibiotic treatment for Clostridium difficile-associated diarrhea in adults

1 reference

12 December 2020

Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. American College of Gastroenterology, Practice Parameters Committee

1 reference

12 December 2020

Novel Risk Factors forClostridium difficile–Associated Disease in a Setting of Endemicity?

1 reference

12 December 2020

Antibodies to recombinant Clostridium difficile toxins A and B are an effective treatment and prevent relapse of C. difficile-associated disease in a hamster model of infection.

1 reference

12 December 2020

Treatment of recurrent Clostridium difficile-associated diarrhoea with a suspension of donor faeces

1 reference

12 December 2020

The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii

1 reference

12 December 2020

Antibiotic-associated colitis due to Clostridium difficile: double-blind comparison of vancomycin with bacitracin.

1 reference

12 December 2020

Rifampin plus metronidazole for Clostridium difficile infection

1 reference

12 December 2020

Inpatient mortality and death reporting associated with Clostridium difficile infection in a large teaching hospital

1 reference

12 December 2020

Probiotics for treatment of Clostridium difficile-associated colitis in adults

1 reference

12 December 2020

Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients

1 reference

12 December 2020

10.2165/11591230-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

24 August 2017

1015843821

0 references

1 reference